WHIPPANY, N.J., Nov. 21, 2017 /PRNewswire/ -- Bayer® Aspirin has been awarded the Consumer Healthcare Products Association 2017 Industry Leadership Award for Advancing Self-Care for its marketing campaign, "The HeroSmiths." The brand's national effort aimed to educate people of the life-saving benefits of aspirin during a suspected heart attack and empower them to become everyday heroes by carrying Bayer® Aspirin at all times.
The Consumer Healthcare Products Association (CHPA) is a highly regarded member-based trade association, for leading manufacturers and marketers of over-the-counter medicines and dietary supplements. CHPA's vision is "Happier, healthier lives through responsible self-care." Each year, the organization awards one CHPA member company with the prestigious Industry Leadership Award for Advancing Responsible Self-Care, honoring educational efforts that have created a positive impact on the consumer healthcare industry and, as a result, have directly advanced responsible self-care for U.S. consumers.
In the U.S., there is a heart attack every 42 seconds. During a suspected heart attack, chewing aspirin as directed by a doctor can help increase the chances of survival*. In an effort to help save lives, the Bayer® Aspirin "HeroSmiths" program, which launched in February of 2017, seeks to educate people everywhere to carry aspirin in the event that someone nearby suffers a heart attack.
"Building a movement based on consumer needs and one that blends education with action is the epitome of advancing responsible self-care, and it's an honor for us to be recognized," said Natalie Bartner, President of Bayer Consumer Health in North America. "The HeroSmiths campaign has the potential to quite literally save lives, and we're proud that Bayer aspirin can help people become heroes."
In the event of a suspected heart attack, immediately call 9-1-1 and chew or crush and swallow aspirin as directed by a doctor.
*Chewing aspirin during a suspected heart attack and for 30 days thereafter decreases the chance of dying by 23%.(1)
(1) ISIS-2 (Second International Study of Infarct Survival) Collaborative Group. Randomised trial of intravenous streptokinase, oral aspirin, both, or neither among 17,187 cases of suspected acute myocardial infarction: ISIS-2. Lancet 1988; 2:349- 60.
Bayer: Science For A Better Life
Bayer is a global enterprise with core competencies in the Life Science fields of health care and agriculture. Its products and services are designed to benefit people and improve their quality of life. At the same time, the Group aims to create value through innovation, growth and high earning power. Bayer is committed to the principles of sustainable development and to its social and ethical responsibilities as a corporate citizen. In fiscal 2016, the Group employed around 115,200 people and had sales of EUR 46.8 billion. Capital expenditures amounted to EUR 2.6 billion, R&D expenses to EUR 4.7 billion. These figures include those for the high-tech polymers business, which was floated on the stock market as an independent company named Covestro on October 6, 2015. For more information, go to www.bayer.us.
Mobile: (862) 246-5028